4 completed, 1 withdrawn. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Devic's Disease: new trials by email Literature Review of Devic's Disease trials Research Report on Devic's Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 | |
| A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Tocilizumab - Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica | Phase 1 / Phase 2 | Completed | Fu-Dong Shi | 10 | 2017-02-01 | 2024-04-11 |
| Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Autologous mesenchymal stem cells - Devic's Syndrome, Devic's Neuromyelitis Optica | Phase 2 | Completed | Tianjin Medical University General Hospital | 15 | 2013-01-01 | 2018-10-17 |
| Hematopoietic Stem Cell Transplant in Devic's Disease Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF - Devic's Disease | Phase 1 / Phase 2 | Completed | Northwestern University | 13 | 2009-10-10 | 2020-02-28 |
| An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Eculizumab - Neuromyelitis Optica, Devic's Disease | Phase 1 / Phase 2 | Completed | Mayo Clinic | 14 | 2009-04-01 | 2013-11-04 |
Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Cranial Nerve Diseases (5) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Eye Diseases (5) · Immune System Diseases (5) · Myelitis, Transverse (5) · Nervous System Diseases (5) · Optic Nerve Diseases (5) · Optic Neuritis (5)
Antilymphocyte Serum (2) · Cyclophosphamide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Mesna (2) · Methylprednisolone (2) · Methylprednisolone Acetate (2) · Methylprednisolone Hemisuccinate (2) · Rituximab (2) · thymoglobulin (2) · Hematopoietic Stem Cell Transplantation (1) · Immunoglobulin G (1) · Immunoglobulins, Intravenous (1) · Octagam (1) · eculizumab (1)
Northwestern University (2) · Fu-Dong Shi (1) · Mayo Clinic (1) · Tianjin Medical University General Hospital (1)
United States (3) · China (2)
Fu-Dong Shi, MD,PhD (2) · Richard Burt, MD (2) · Sean J. Pittock, M.D. (1)